Travere Therapeutics (TVTX)

• Market cap: $5.38B
• 1 day: 0.84%
• 5 days: 4.27%
• 1 month: -0.79%
• 3 months: 41.73%
• 6 months: 92.61%
• Year to date: 46.36%
• 1 year: 275.58%
• 5 years: 320.35%
• 10 years: 214.35%
• Sector: Healthcare
• Industry: Biotechnology

About: Travere Therapeutics Inc is a biopharmaceutical company. The company is focused on identifying, developing and delivering life-changing therapies to people living with rare kidney, liver, and metabolic diseases. Its pipeline candidate, sparsentan, is an investigational product candidate in late-stage development for focal segmental glomerulosclerosis (FSGS) and IgA nephropathy (IgAN)-rare kidney disorders that often cause end-stage kidney disease. It is also advancing pegtibatinase, a novel investigational enzyme replacement therapy for the treatment of HCU, a genetic disorder caused by a deficiency in a pivotal enzyme essential to the body.

Employees: 497